Hyperbaric Oxygen Therapy Promotes Hearing Gain with Increases in Serum IGF-1 and HSP70 in Patients with Idiopathic Sudden Sensorineural Hearing Loss

Table 1

Demographic data, comorbidities, and audiometric characteristics of the study cohort.

Clinical characteristics	ISSHL groups		Health control (n = 30)	value
	HBOT + MT group (n = 35)	MT group (n = 35)
Sex (%)				0.83
Male	15 (42.9%)	17 (48.6%)	15 (50%)
Female	20 (67.1%)	18 (51.4%)	15 (50%)
Age (years, (mean ± SD))	47.9 ± 15.9	43.5 ± 15.2	44.9 ± 10.3	0.24
Comorbidities (%)
Hypertension	12 (34.3%)	14 (40.0%)		0.42
Type 2 diabetes	9 (25.7%)	7 (20%)		0.39
Hyperlipidemia	14 (40%)	11 (31.4%)		0.31
Accompanying symptom (%)
Tinnitus	29 (82.9%)	26 (74.3%)		0.56
Dizzy	12 (34.3%)	16 (45.7%)		0.47
Visit time (days, (mean ± SD))	4.3 ± 2.0	3.9 ± 2.4		0.49
Affected ear (%)
Left	19 (54.3%)	20 (57.1%)		0.80
Right	16 (45.7%)	15 (42.9%)
Degree of hearing loss (%)				0.24
Moderate-severe (56–70 dB)	9 (25.7%)	13 (37.1%)
Severe (71–90 dB)	22 (62.9%)	16 (45.7%)
Profound (≥91 dB)	4 (11.4%)	6 (17.1%)

HBOT + MT group: HBOT and medical therapy group; MT group: medical therapy group.